Frank R. Witney

Frank, who joined Ampersand as an Operating Partner in 2016, served as Chairman of Gyros Protein Technologies and currently serves on the boards of Canopy Biosciences and Nexcelom, and as an active Board Observer of GenDx. Frank most recently served as CEO of Affymetrix, a leading provider of genomics and cell biology products that was sold in 2016 for $1.3 billion. Previously, Frank was CEO of Dionex, a leading provider of analytical instrumentation that was sold in 2011 for $2.1 billion. He also held senior executive positions at Perkin Elmer, Packard Bioscience and Bio-Rad Laboratories. Frank holds a Ph.D. in molecular and cellular biology from Indiana University.